Palantir Upgraded on Growth of Bespoke AI Software Market -- Market Talk
Dow Jones2026/10/08 17:251325 ET - Palantir is positioned to benefit as the growth of the market for bespoke software and sovereign AI outpaces that of the market for packaged software, according to Goldman Sachs in a note. Palantir is expanding its vertical model deeper into financials services, semiconductors, and neoclouds, analysts Gabriela Borges and Maura Hager say, while enterprises are increasingly looking to build AI tools that capitalize on their existing operating moats and aren't reliant on frontier models. They also say Palantir has a head start in using AI agents as forward-deployed engineers, and that the company has an opportunity to expand its work with the U.S. government. Goldman upgrades Palantir to buy from neutral. Palantir is up 1.6%. (elias.schisgall@wsj.com) (END) Dow Jones Newswires October 08, 2026 13:25 ET (17:25 GMT)
1325 ET - Palantir is positioned to benefit as the growth of the market for bespoke software and sovereign AI outpaces that of the market for packaged software, according to Goldman Sachs in a note. Palantir is expanding its vertical model deeper into financials services, semiconductors, and neoclouds, analysts Gabriela Borges and Maura Hager say, while enterprises are increasingly looking to build AI tools that capitalize on their existing operating moats and aren't reliant on frontier models. They also say Palantir has a head start in using AI agents as forward-deployed engineers, and that the company has an opportunity to expand its work with the U.S. government. Goldman upgrades Palantir to buy from neutral. Palantir is up 1.6%. (elias.schisgall@wsj.com)
(END) Dow Jones Newswires
October 08, 2026 13:25 ET (17:25 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
